Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80639
Name bone sarcoma
Definition A bone cancer that has_material_basis_in abnormally proliferating cells derives from embryonic mesoderm.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer bone cancer bone sarcoma


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02389244 Phase II Regorafenib A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Recruiting FRA 0
NCT02992912 Phase II Atezolizumab Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) Active, not recruiting FRA 0
NCT03838042 Phase Ib/II Entinostat + Nivolumab INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt) Recruiting NLD | FRA | DEU | AUT | AUS 2
NCT03986606 Phase I PSB205 A Study of PSB205 in Subjects With Advanced Solid Tumors Unknown status USA 0
NCT04055220 FDA approved Regorafenib Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (REGOSTA) Recruiting FRA 0
NCT04698785 Phase II Regorafenib Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients (REGOMAIN) Recruiting FRA 0
NCT04784247 Phase II Lenvatinib + Pembrolizumab Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma Active, not recruiting USA 0
NCT05253131 Phase Ib/II AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas Not yet recruiting USA 0
NCT05621668 Phase I AttIL12 T-cells + Cyclophosphamide A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma Recruiting USA 0
NCT06021626 Phase I CRD3874 A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer Recruiting USA 0